Khosla Ventures is a technology investor whose AI investments connect foundation models with applications in healthcare and autonomous systems. Its disclosed positions include OpenAI, Abridge and Waabi, covering both the development of general AI capabilities and products built for specific industries.
A model developer, a clinical application and an autonomous-system company reach users through very different channels. Their common AI connection does not make their product cycles or capital requirements interchangeable.
Clinical and autonomous applications must work under constraints that are not captured by a general language-model benchmark. Evidence of safe, repeatable performance can become a substantial part of the business itself.
More capable models can expand a market while leaving deployment expensive. Investors and founders still need to distinguish research costs, ongoing inference, operational support and the resources required to enter a regulated workflow.
Selected disclosed relationships, reviewed November 4, 2026. Each source supports the investment relationship; this is not a complete portfolio or a statement of current holdings.
Clinical documentation must fit professional practice and medical record workflows, while autonomous driving must handle changing physical conditions. Both depend on AI research, but the steps toward dependable use are different. The pairing is useful for examining deployment work that a general model benchmark cannot resolve on its own.
They expose different parts of the AI value chain. Models supply capabilities, clinical software adapts those capabilities to professional work, and autonomous systems connect learning to physical operation. The comparison helps identify deployment constraints; it does not imply that these businesses share the same economics or financing structure.
A clinical tool must fit care delivery, record systems and professional accountability. General benchmarks can help measure a model’s capabilities, but they do not establish whether a workflow is safe, reliable or useful in a specific health system. Deployment evidence needs to address those operational requirements directly.
Autonomous systems must account for physical conditions, sensors, failure handling and operational deployment. Those requirements can introduce testing and support costs beyond ordinary software distribution. AI capability is part of the product, but it cannot substitute for evidence that the complete system behaves reliably in its intended environment.
Progress in general model capabilities does not establish that an autonomous system can operate reliably in its intended environment. Physical sensing, control and failure handling need their own evidence. Reading these investments together is useful precisely because the connection to AI does not erase their distinct technical and operational requirements.
Research risk concerns whether a needed capability can be achieved. Deployment risk concerns whether a system works reliably, integrates with users and supports a viable business. A company can reduce one while still facing the other. The model, healthcare and autonomy examples in this profile make that distinction useful.
